Zydus Lifesciences Ltd
Pharmaceuticals & Biotechnology | Large Cap
Zydus Lifesciences demonstrates a strong financial standing, particularly excelling in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases substantial growth in revenue, operating profit, and earnings per share. Strong coverage ratios indicate a robust ability to meet interest and dividend obligations. Excellent profitability metrics, including high returns on capital, equity, and assets, further underscore the company's financial health. However, there are areas needing attention, notably in liquidity and efficiency. While the company maintains a reasonable liquidity position, it is not exceptionally strong. Efficiency ratios reveal challenges in asset utilization, especially concerning fixed assets, inventory, and receivables. Capital expenditure is also relatively high, which could impact short-term cash flow. Despite these challenges, Zydus Lifesciences' strong performance in key areas suggests a positive outlook, driven by growth and profitability.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio8.00
- Profitability Ratio10.00
- Efficiency Ratio2.67
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio4.68
- Peer Assessment
- Management AssessmentStrong
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthBullish
Zydus Lifesciences demonstrates a strong financial standing, particularly excelling in solvency, growth, coverage, and profitability. The company efficiently manages its debt and showcases substantial growth in revenue, operating profit, and earnings per share. Strong coverage ratios indicate a robust ability to meet interest and dividend obligations. Excellent profitability metrics, including high returns on capital, equity, and assets, further underscore the company's financial health. However, there are areas needing attention, notably in liquidity and efficiency. While the company maintains a reasonable liquidity position, it is not exceptionally strong. Efficiency ratios reveal challenges in asset utilization, especially concerning fixed assets, inventory, and receivables. Capital expenditure is also relatively high, which could impact short-term cash flow. Despite these challenges, Zydus Lifesciences' strong performance in key areas suggests a positive outlook, driven by growth and profitability.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
30.27
Industry Median
28.62
Large Cap Median
30.25
P/E RATIO
21.38
P/B RATIO
3.98
Industry Median
3.17
Large Cap Median
5.04
P/S RATIO
3.96
Industry Median
3.42
Large Cap Median
5.48
Others
PEG RATIO
0.00
EV/EBITDA RATIO
12.99
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1070.8 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤6th Nov 25
Q2 FY26 Post Results Earnings Call
NEUTRAL SENTIMENT
The company demonstrates robust growth across key metrics. The revenue growth rate is impressive, indicating strong market demand and effective sales strategies. The operating profit growth rate is also substantial, showing improved operational efficiency and cost management. The earnings per share (EPS) growth is exceptional, reflecting increased profitability and shareholder value. The asset growth rate indicates that the company is expanding its asset base. The net income growth rate is also significant, confirming overall financial health. The weighted average calculation further reinforces this positive trend, highlighting consistent and sustainable growth patterns.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.08 | 12.92 | 13.4 | 18.9 | 16.81 |
| Operating Profit Growth Rate | -0.06 | 15.5 | 39.48 | 31.09 | 20.08 |
| Earnings Per Share (EPS) Growth | 110.32 | -55.81 | 98.04 | 17.23 | 11.39 |
| Asset Growth Rate | 16.31 | -7.52 | 12.8 | 27.24 | 42.84 |
| Net Income Growth Rate | 111.35 | -54.7 | 89.91 | 17.62 | 9.65 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. Adjusted earnings per share (EPS) and cash EPS are strong, reflecting good profitability on a per-share basis. Book value per share is also high, indicating a substantial net asset value for each share. Dividend per share is reasonable, providing returns to shareholders. However, capital expenditures are relatively high, which could impact short-term cash flow. While the company demonstrates solid earnings and asset value, managing capital expenditures efficiently is crucial for maintaining financial stability.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 45.36 | 26.26 | 40.47 | 48.93 | 55.45 |
| Cash Earnings Per Share (Cash EPS) | 52.26 | 27.87 | 46.9 | 55.34 | 64.67 |
| Book Value Per Share | 166.66 | 173.43 | 196.34 | 237.16 | 268.44 |
| Dividend Per Share (DPS) | 2.63 | 6 | 3.07 | 10.79 | 1 |
| Capital Expenditures (CapEx) | 1055 | 992 | 883 | 1662 | 2647 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability. The gross profit margin indicates efficient cost management. The return on capital employed (ROCE), return on equity (ROE), and return on assets (ROA) are all high, reflecting effective utilization of capital and assets. The operating margin and net margin further confirm strong profitability. This high profitability provides financial strength and flexibility. This enables the company to reinvest in growth opportunities and provide returns to shareholders. The weighted average calculation further supports this assessment, highlighting consistent and sustainable profitability patterns.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 17.22 | 18.2 | 23.64 | 26.43 | 26.03 |
| Return on Capital Employed (ROCE) | 13 | 15 | 22 | 24 | 21 |
| Return on Equity (ROE) | 27.17 | 11.94 | 20.04 | 19.51 | 18.9 |
| Return on Assets (ROA) | 12.09 | 15.1 | 18.67 | 19.24 | 16.17 |
| Operating Margin | 21.89 | 22.39 | 27.54 | 30.37 | 31.22 |
| Net Margin | 30.25 | 12.14 | 20.33 | 20.11 | 18.87 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios indicate areas where the company faces challenges in asset utilization. The fixed asset turnover ratio is low, suggesting that the company is not generating enough revenue from its fixed assets. The inventory turnover ratio indicates that the company may have obsolete or slow-moving inventory. The receivables turnover ratio suggests that the company takes longer to collect payments from its customers. The days sales in inventory and receivable days further confirm these inefficiencies. The capital turnover ratio is also low, indicating that the company is not efficiently using its capital to generate revenue. Addressing these inefficiencies can improve the company's overall financial performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.25 | 1.5 | 1.58 | 1.77 | 1.02 |
| Inventory Turnover Ratio | 3.63 | 3.95 | 4.36 | 4.63 | 4.2 |
| Receivables Turnover Ratio | 4.72 | 4.44 | 4.06 | 5.03 | 5.75 |
| Days Sales in Inventory Ratio | 100.55 | 92.41 | 83.72 | 78.83 | 86.9 |
| Receivable Days | 77.33 | 82.21 | 89.9 | 72.56 | 63.48 |
| Capital Turnover Ratio | 0.88 | 0.98 | 0.98 | 0.97 | 0.88 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are exceptionally strong. The interest coverage ratio indicates a robust ability to meet interest obligations, reflecting sound financial management. The equity dividend coverage ratio is also high, demonstrating a strong capacity to cover dividend payments to shareholders. These high coverage ratios provide financial stability and flexibility. This enables the company to manage its debt and dividend obligations effectively. The weighted average calculation further supports this assessment, highlighting consistent and conservative coverage practices.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 41.03 | 20.88 | 60.65 | 37.31 | 16.08 |
| Equity Dividend Coverage Ratio | 16.67 | 3.23 | 12.5 | 4.17 | 50 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits exceptional solvency. The debt ratio and debt-to-equity ratio are very low, indicating minimal reliance on debt financing. The equity ratio is nearly perfect, showing that the company is primarily financed by equity. The debt-to-asset ratio is also minimal, confirming that the company's assets are not funded by debt. This strong solvency position provides financial stability and flexibility. This enables the company to pursue growth opportunities without being burdened by excessive debt obligations. The weighted average calculation further supports this assessment, highlighting consistent and conservative debt management practices.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.02 | 0 | 0 | 0 | 0.13 |
| Debt to Equity Ratio | 0.02 | 0 | 0 | 0 | 0.15 |
| Equity Ratio | 0.98 | 1 | 1 | 1 | 0.87 |
| Debt To Asset Ratio | 0.01 | 0 | 0 | 0 | 0.07 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reflects a mixed performance. While the current and quick ratios suggest an ability to cover short-term liabilities, they aren't exceptionally high. The cash ratio indicates a lower proportion of cash holdings compared to current liabilities. The operating cash flow ratio, while positive, suggests reliance on operational cash for short-term obligations. On the positive side, the company has increased its current ratio in recent years. However, maintaining sufficient liquid assets to meet immediate obligations remains crucial for financial stability.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.41 | 1.43 | 1.14 | 0.8 |
| Quick Ratio | 0.75 | 0.98 | 1.05 | 0.83 | 0.53 |
| Cash Ratio | 0.11 | 0.07 | 0.12 | 0.23 | 0.07 |
| Operating Cash Flow Ratio | 0.21 | 0.34 | 0.36 | 0.53 | 0.1 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.89 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | Alkem Laboratories Ltd | 8.08 | 27.91 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 4 | Lupin Ltd | 7.84 | 20.16 | Neutral | 8816.00 | 139.25 | 5355.00 |
| 5 | Cipla Ltd | 7.62 | 28.15 | Neutral | 5883.00 | 43.52 | 3862.00 |
| 6 | Mankind Pharma Ltd | 7.61 | 52.10 | Highly Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | Zydus Lifesciences Ltd | 7.60 | 21.38 | Neutral | 8475.00 | 35.38 | 5124.00 |
| 8 | Laurus Labs Ltd | 7.10 | 85.84 | Neutral | 1778.00 | 13.72 | 890.00 |
| 9 | Dr Reddys Laboratories Ltd | 6.49 | 25.31 | Neutral | 6454.00 | 38.58 | 4158.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 45.87 | Neutral | 4572.00 | -7.12 | 1362.00 |
Overall, Zydus Lifesciences demonstrates effective management, as evidenced by strong financial performance and increasing operational efficiency. The company has shown consistent sales and profit growth, coupled with a rising OPM. Prudent capital management is reflected in healthy ROCE and ROE figures. While there is a slight increase in debt, it appears to be manageable. High promoter holding indicates confidence and alignment with shareholder interests.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (TTM) | 19% | Strong revenue expansion |
| Profit Growth (TTM) | 21% | Strong and sustainable profit growth | |
| OPM (Mar 2025) | 33% | Improving operational efficiency | |
| ROCE (Mar 2025) | 24% | Productive use of capital | |
| CONS | Borrowings (Mar 2025) | ₹ 3,213 Cr. | Moderate Increase in Borrowings |
| Other Income Contribution (Mar 2023) | -₹422 Cr | Profitability affected by Other Income |
Financial Performance & Growth
Zydus Lifesciences demonstrates strong financial performance and growth, highlighted by robust sales and profit growth. The company shows consistent revenue expansion and profitability.
Strong Profit Growth
The compounded profit growth reflects a positive trend, indicating the company's increasing profitability over different periods. The TTM profit growth is particularly strong.
| Metric | 2016–2018 | 2019–2021 | 2022–2024 | 2025 |
|---|---|---|---|---|
| Compounded Profit Growth | 22.41% | 1.56% | 26.31% | 21% |
The YOY profit growth has been strong, particularly in recent quarters. The EPS has also shown substantial increases in recent quarters, reflecting the improved profitability of the company.
Capital Efficiency & Returns
Zydus Lifesciences exhibits notable capital efficiency and returns, primarily driven by strong ROCE figures. These metrics indicate that the company is effectively utilizing its capital and generating substantial returns for its shareholders.
High Return on Capital Employed (ROCE)
Zydus Lifesciences consistently demonstrates a strong Return on Capital Employed (ROCE), indicating effective capital utilization. The ROCE % has seen fluctuations over the years, but it generally remains at a healthy level. The recent increase in ROCE to 24% in Mar 2025 suggests that the company's capital management is improving.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 22.67% | 16.33% | 12.67% | 15% | 22% | 24% |
Financial Health & Prudence
Zydus Lifesciences demonstrates overall good financial health and prudence, although there are some areas that warrant attention. The company maintains a manageable debt level, but there has been a recent increase in borrowings. The interest coverage ratio remains strong, indicating that the company can comfortably cover its interest obligations. The dividend payout is inconsistent, which may concern some investors.
Moderate Increase in Borrowings
While the debt-to-equity ratio is low, the borrowings have increased in the most recent year. This increase in borrowings could be a concern if not managed properly.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr.) | 2597.67 | 6171.00 | 4350.00 | 1195 | 804 | 3213 |
Strategic & Operational Indicators
Zydus Lifesciences exhibits mixed strategic and operational indicators. While the company shows improvements in sales growth and profitability, there are some concerns regarding working capital management. The cash conversion cycle has fluctuated but generally remains high, indicating potential inefficiencies in managing working capital. Fixed asset management appears strategic, with continuous investments in gross block and CWIP.
Increased Working Capital Days
The working capital days have been increasing over the years, indicating that the company is taking longer to convert its working capital into revenue. An increase in working capital days suggests that the company may be facing challenges in managing its operational cycles efficiently.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Working Capital Days | 49.67 | 85.33 | 95.33 | 95 | 103 | 129 |
The risk assessment for Zydus Lifesciences indicates a moderate level of risk. The primary concern is the segment performance volatility, as evidenced by fluctuations in quarterly sales and profit growth. There is a need for proactive risk management to ensure sustained financial health.
Segment performance volatility
Segment performance volatility is evident in the fluctuations of quarterly sales and profit growth.
Fluctuations in Quarterly Sales and Profit Growth
The quarterly results show volatility in both sales and profit growth.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| YOY Sales Growth (%) | 3.69% | 31.66% | 10.44% | 17.96% |
| YOY Profit Growth (%) | -45% | 48% | 95% | 6% |
Foreign exchange or interest rate exposure
The company's exposure to foreign exchange or interest rate fluctuations could affect profitability and financial stability.
Contingent liability evaluation
There is a need for continuous monitoring of contingent liabilities to prevent unexpected financial strain.
Regulatory compliance cost trends
Changes in regulations and compliance requirements could lead to increased costs, affecting profitability.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101072.51Bearish
- SMA 201069.24Bullish
- SMA 501084.59Bearish
- EMA 101071.54Bullish
- EMA 201072.88Bearish
- EMA 501079.55Bearish
- DEMA 101071.34Bullish
- DEMA 201068.47Bullish
- DEMA 501073.36Bearish
- TEMA 101071.99Bullish
- TEMA 201070.71Bullish
- TEMA 501063.65Bullish
- MACD-2.80Bullish
- ADX21.39Weak Trend
- IndicatorValueSignal
- RSI46.57Neutral
- CCI33.86Neutral
- ROC 9-0.06Bearish
- ROC 140.87Bullish
- ROC 25-0.52Bearish
- Stoch K51.66Neutral
- Stoch D53.08Neutral
- IndicatorValueSignal
- BB Upper1081.06Neutral
- BB Middle1069.24Neutral
- BB Lower1057.41Neutral
- ATR6.78Low Volatility
- IndicatorValueSignal
- MFI65.45Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101070.31Bullish
- SMA 201075.18Bearish
- SMA 501088.11Bearish
- EMA 101072.29Bearish
- EMA 201076.48Bearish
- EMA 501078.73Bearish
- DEMA 101069.52Bullish
- DEMA 201068.80Bullish
- DEMA 501089.16Bearish
- TEMA 101071.86Bullish
- TEMA 201065.61Bullish
- TEMA 501072.19Bullish
- MACD-5.52Bullish
- ADX17.06Weak Trend
- IndicatorValueSignal
- RSI44.39Neutral
- CCI-36.83Neutral
- ROC 91.07Bullish
- ROC 14-0.16Bearish
- ROC 25-3.08Bearish
- Stoch K54.22Neutral
- Stoch D51.59Neutral
- IndicatorValueSignal
- BB Upper1095.12Neutral
- BB Middle1075.18Neutral
- BB Lower1055.25Neutral
- ATR9.49Low Volatility
- IndicatorValueSignal
- MFI40.18Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101073.62Bearish
- SMA 201087.45Bearish
- SMA 501070.05Bullish
- EMA 101075.36Bearish
- EMA 201078.96Bearish
- EMA 501057.67Bullish
- DEMA 101068.30Bullish
- DEMA 201080.38Bearish
- DEMA 501106.82Bearish
- TEMA 101065.81Bullish
- TEMA 201066.32Bullish
- TEMA 50N/AN/A
- MACD-0.47Bearish
- ADX19.03Weak Trend
- IndicatorValueSignal
- RSI47.75Neutral
- CCI-88.11Neutral
- ROC 9-1.52Bearish
- ROC 14-2.26Bearish
- ROC 25-0.19Bearish
- Stoch K27.75Neutral
- Stoch D25.72Neutral
- IndicatorValueSignal
- BB Upper1119.68Neutral
- BB Middle1087.44Neutral
- BB Lower1055.21Neutral
- ATR15.59Low Volatility
- IndicatorValueSignal
- MFI27.54Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101087.55Bearish
- SMA 201082.48Bearish
- SMA 50999.48Bullish
- SMA 100948.60Bullish
- SMA 200954.52Bullish
- EMA 101079.42Bearish
- EMA 201067.38Bullish
- EMA 501017.70Bullish
- EMA 100979.65Bullish
- EMA 200960.78Bullish
- DEMA 101081.14Bearish
- DEMA 201101.12Bearish
- DEMA 501079.67Bearish
- DEMA 1001021.13Bullish
- DEMA 200976.98Bullish
- TEMA 101068.56Bullish
- TEMA 201092.41Bearish
- TEMA 501112.98Bearish
- TEMA 1001063.96Bullish
- TEMA 200990.21Bullish
- MACD22.22Bearish
- ADX43.18Strong Trend
- IndicatorValueSignal
- RSI55.72Neutral
- CCI-50.43Neutral
- ROC 14-1.87Bearish
- ROC 257.98Bullish
- Stoch K28.16Neutral
- Stoch D32.78Neutral
- IndicatorValueSignal
- BB Upper1113.31Neutral
- BB Middle1082.48Neutral
- BB Lower1051.66Neutral
- ATR25.26Low Volatility
- IndicatorValueSignal
- MFI42.17Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20945.23Bullish
- SMA 50954.18Bullish
- EMA 20975.36Bullish
- EMA 50953.35Bullish
- DEMA 201016.03Bullish
- DEMA 50967.87Bullish
- TEMA 201056.93Bullish
- TEMA 50964.82Bullish
- MACD37.13Bullish
- ADX20.83Weak Trend
- IndicatorValueSignal
- RSI66.19Neutral
- CCI206.21Overbought
- ROC 1420.99Bullish
- ROC 2520.13Bullish
- Stoch K90.57Overbought
- Stoch D87.67Overbought
- IndicatorValueSignal
- BB Upper1091.76Overbought
- BB Middle945.23Neutral
- BB Lower798.69Neutral
- ATR55.06Low Volatility
- IndicatorValueSignal
- MFI86.63Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6927.02Bullish
- SMA 12950.15Bullish
- SMA 24975.41Bullish
- EMA 6954.99Bullish
- EMA 12945.49Bullish
- EMA 24915.81Bullish
- DEMA 6975.67Bullish
- DEMA 12956.43Bullish
- DEMA 241002.16Bullish
- TEMA 61001.11Bullish
- TEMA 12946.82Bullish
- TEMA 24965.80Bullish
- MACD120.41Bearish
- ADX23.69Weak Trend
- IndicatorValueSignal
- RSI61.67Neutral
- CCI74.59Neutral
- ROC 2513.02Bullish
- ROC 50209.24Bullish
- Stoch K38.66Neutral
- Stoch D51.33Neutral
- IndicatorValueSignal
- BB Upper1048.15Overbought
- BB Middle944.61Neutral
- BB Lower841.07Neutral
- ATR103.10High Volatility
- IndicatorValueSignal
- MFI55.75Neutral